No Picture
News

AstraZeneca promotes oncology exec to CMO; Pfizer replaces retiring chief dealmaker as war chest expands

Cristian Massacesi The biggest bright spot for AstraZeneca over the last few years has been its work in oncology, as CEO Pascal Soriot has helped shepherd blockbusters Imfinzi, Lynparza, and Calquence, among other cancer medicines. One of the top executives from the cancer division is now… Click here to view original post… […]


ADVERTISEMENT — Advertise With Biotech Networks
No Picture
News

Pardes Biosciences Initiates First-in-Human Trial for PBI-0451, an Oral Antiviral in Development to Treat and Prevent SARS-CoV-2 Infections

CARLSBAD, Calif., Aug. 26, 2021 (GLOBE NEWSWIRE) — Pardes Biosciences, Inc., a clinical-stage biopharmaceutical company today announced the initiation of a Phase 1 clinical trial, evaluating the company’s lead candidate, PBI-0451 which is being developed as a potential oral direct-acting antiviral to treat and prevent infections with SARS-CoV-2, the… Click here to view original post… […]

No Picture
News

Sorrento Reports Promising Results With mRNA Vaccine For COVID-19 Delivered With The MuVaxx Lymphatic Drug Delivery Device

SAN DIEGO, Aug. 26, 2021 (GLOBE NEWSWIRE) — Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), a clinical and commercial stage biopharmaceutical company developing new therapies to treat cancer, pain (non-opioid treatments), autoimmune disease and COVID-19, today announced promising preclinical results for its mRNA vaccine against SARS-CoV-2. STI-mRNA is comprised of… Click here to view original post… […]

No Picture
News

Sorrento Exercises Exclusive Option Agreement With Texas A&M University for MPRO Inhibitors Against Sars-Cov-2 and all Variants of Concern

SAN DIEGO, Aug. 26, 2021 (GLOBE NEWSWIRE) — Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) announced today that it has notified The Texas A&M University System (“TAMUS”) of its exercise of the option to an exclusive license for the global development and commercialization of highly potent main protease (MPro) inhibitors… Click here to view original post… […]


ADVERTISEMENT — Advertise With Biotech Networks
No Picture
News

Growth-promoting, Anti-aging Retinal at the Root of Plant Growth Too

Publishing in the journal Science, a research team led by new UC San Diego biologist Alexandra Dickinson has identified a compound that plays a key role in triggering the development of plants’ lateral roots. Retinoids, known for medical uses, were found to be vital in plant… Click here to view original post… […]

No Picture
News

Sanford Burnham Prebys drug enters Phase 1 study for the treatment of tobacco use disorder

A drug discovered in the lab of Nicholas Cosford, Ph.D., professor and director of the NCI-designated Cancer Center at Sanford Burnham Prebys, has entered a Phase 1 clinical study. The compound, SBP-9330, targets a neuronal signaling pathway underlying addictive behaviors and would be a first-in-class oral therapeutic to help people… Click here to view original post… […]

No Picture
News

Massive Study Links Nearly 600 Genomic Regions to Self-Regulating Behaviors

Researchers identified 579 locations in the human genome associated with a predisposition to self-regulation-related behaviors, such as addiction. With data from 1.5 million people of European descent, the effort is one of the largest genome-wide association studies to date. Click here to view original post… […]


ADVERTISEMENT — Advertise With Biotech Networks
No Picture
News

Lassen Therapeutics to Present at the 5th Annual Idiopathic Pulmonary Fibrosis (IPF) Summit

SAN DIEGO–(BUSINESS WIRE)–Lassen Therapeutics, a biotech company developing innovative therapeutic antibodies as potential treatments for fibrosis, rare diseases and oncology, today announced that Jamie Swaney, Ph.D., Vice President of Fibrosis & Translational Biology, is presenting at the 5th Annual IPF Summit on Friday, August 27, 2021. The title of his… Click here to view original post… […]

No Picture
News

BioDuro-Sundia plants its flag at former Par manufacturing site in CA

A former Par Pharma site in Irvine, CA, will now have a new tenant. BioDuro-Sundia will acquire a 40,000-square-foot oral solid dose manufacturing site in Irvine, the company announced Monday. The site will allow the company to scale up and cater to companies that need larger-scale… Click here to view original post… […]


ADVERTISEMENT — Advertise With Biotech Networks
No Picture
News

Research reveals how subtle changes in a microRNA may lead to ALS

LA JOLLA—When people think about the connection between genes and disease, they often envision something that works like a light switch: When the gene is normal, the person carrying it does not have the disease. If it gets mutated, a switch is flipped, and then they do have it. The… Click here to view original post… […]

No Picture
News

TumorGen Receives $390K NCI Grant to Counter Metastasis

SAN DIEGO–(BUSINESS WIRE)–TumorGen Inc., a biotechnology company, has received a $390,000 Small Business Innovation Research (SBIR) grant from the National Cancer Institute (NCI) to validate a revolutionary microfluidic platform used to develop anti-metastatic therapies. With this funding, the company will test the new technology in lung cancer patients, capturing metastatic… Click here to view original post… […]

No Picture
News

Halozyme to Present at Wells Fargo 2021 Virtual Healthcare Conference

SAN DIEGO: SAN DIEGO, Aug. 26, 2021 /PRNewswire/ — Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that Dr. Helen Torley, president and chief executive officer, will present at the Wells Fargo 2021 Virtual Healthcare Conference on Friday, September 10, 2021 at 10:40 a.m. Eastern Time / 7:40 a.m. Pacific Time…. Click here to view original post… […]


ADVERTISEMENT — Advertise With Biotech Networks
No Picture
News

Scientist.com Named to Inc. Magazine’s ‘Honor Roll’ of Fastest-Growing Private Companies in the US

SAN DIEGO–(BUSINESS WIRE)– #biopharma–Inc. magazine today announced that Scientist.com, the healthcare industry’s leading marketplace for life science research, ranked no. 1701 on its annual Inc. 5000 list, a ranking of the United States’ fastest-growing private companies. This year also marked Scientist.com’s inclusion on the Inc. ‘honor roll’, for companies that… Click here to view original post… […]

No Picture
News

DePuy Synthes to Showcase Innovation Momentum at the American Academy of Orthopaedic Surgeons (AAOS) Annual Meeting

RAYNHAM, Mass.: RAYNHAM, Mass., Aug. 25, 2021 /PRNewswire/ — The Johnson & Johnson Medical Devices Companies* announced that DePuy Synthes,** The Orthopaedics Company of Johnson & Johnson, will feature new products and technology solutions shaping new standards of care for modern day orthopaedics during the American Academy of Orthopaedic Surgeons… Click here to view original post… […]


ADVERTISEMENT — Advertise With Biotech Networks
No Picture
News

Philanthropic donations to Salk Institute exceed record-breaking $100M in FY21

LA JOLLA—The Salk Institute announced today that philanthropic donors gave more than $100 million to support bold scientific research in fiscal year 2021 (ending in June). The amount is a new record in philanthropic gifts for the Institute, eclipsing the previous record gift total in 2019 by more than $11… Click here to view original post… […]

No Picture
News

Avidity Biosciences Announces Changes to its Board of Directors

LA JOLLA, Calif.: LA JOLLA, Calif., Aug. 25, 2021 /PRNewswire/ — Avidity Biosciences, Inc. (Nasdaq: RNA) a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced the appointment of experienced global commercial and operations executive, Eric Mosbrooker to its board of… Click here to view original post… […]

No Picture
News

State Stem Cell Agency Funds Three New UC San Diego Projects

The California Institute for Regenerative Medicine has approved a trio of awards, totaling approximately $4 million, to UC San Diego School of Medicine researchers to advance studies of new stem cell-based treatments for multiple types of cancer and amyotrophic lateral sclerosis. Click here to view original post… […]


ADVERTISEMENT — Advertise With Biotech Networks
No Picture
News

Axel Nimmerjahn leads research team awarded $11 million by the U19 Team-Research BRAIN Circuit Program

LA JOLLA—Salk Associate Professor Axel Nimmerjahn is leading a research team that has been awarded $11.2 million by The Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative, an effort that aims to investigate overarching principles of brain circuit function, including sensation, perception, decision-making and motor control. Nimmerjahn will… Click here to view original post… […]

No Picture
News

Rebus Biosystems Continues Rapid Expansion of Scientific Team

SANTA CLARA, Calif.: SANTA CLARA, Calif., Aug. 25, 2021 /PRNewswire/ — Rebus Biosystems, Inc., ("Rebus Bio"), an Illumina Ventures-backed life science technology company creating revolutionary tools to advance spatial omics research, today announced Tarif Awad, a highly experienced technical and commercial leader within the world of life sciences, has joined… Click here to view original post… […]


ADVERTISEMENT — Advertise With Biotech Networks
No Picture
News

Explora BioLabs Opens New Preclinical Vivarium in San Diego, Calif.

SAN DIEGO: SAN DIEGO, Aug. 25, 2021 /PRNewswire/ — Explora BioLabs, a national provider of industry-leading preclinical vivarium research space and management services based in San Diego, opened a new facility here on August 23, 2021. The new vivarium, located in San Diego’s Sorrento Valley neighborhood, joins five others in… Click here to view original post… […]

No Picture
News

Inside the 30-year hunt for the perfect antibody

John Mascola, America’s soft-spoken, no-nonsense chief vaccinologist, spent 2020 on the fourth floor of the Vaccine Research Center in Bethesda, MD, primarily working on three projects. There’s a decent chance one of them has already been injected in your arm — twice. Another was infused into hundreds of thousands of… Click here to view original post… […]

No Picture
News

Palisade Bio Reports Second Quarter Financial Results and Provides Business Update

CARLSBAD, Calif., Aug. 24, 2021 (GLOBE NEWSWIRE) — Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a late-stage biopharma company advancing therapies for acute and chronic gastrointestinal (GI) complications, today provides a business update and releases its financial results for the second quarter ending June 30, 2021. Click here to view original post… […]


ADVERTISEMENT — Advertise With Biotech Networks
No Picture
News

Sorrento Therapeutics Announces Entry Into Option Agreement to Exclusively License MPRO Inhibitors Against SARS-CoV-2 and Variants of Concern, Including Delta, From Texas A&M University

SAN DIEGO, Aug. 24, 2021 (GLOBE NEWSWIRE) — Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today announced that it has entered into an option agreement (“Option”) with The Texas A&M University System (“TAMUS”) for exclusive rights to the intellectual property covering highly potent main protease (MPro) inhibitors against SARS-CoV-2. This… Click here to view original post… […]

No Picture
News

Progenity Announces Closing of $40 Million Underwritten Public Offering

SAN DIEGO, Aug. 24, 2021 (GLOBE NEWSWIRE) — Progenity, Inc. (“Progenity”) (Nasdaq: PROG), an innovative biotechnology company, today announced the closing of its previously announced underwritten public offering of 40,000,000 shares of its common stock and warrants to purchase up to 40,000,000 shares of its common stock, at a… Click here to view original post… […]